Daniel Bertholet is an Investment Director in the Life Sciences practice at Endeavour Vision, with a focus on medtech investments. Daniel has invested in CeQur, Endoart (sold to Allergan), Thommen Medical (exited), Kuros Biosurgery, Novalar Pharmaceuticals and Neocutis. He also participated in investments and/or follow-on investments in Native Networks, eProject/Daptiv, Paion, Nexx Systems and Novimmune.

Prior to his venture capital career, Daniel was the co-founder and CFO of a technology start-up and has invested as a business angel/private investor in private companies for over 15 years in Europe and the US. Daniel started his career as a consultant in country risk assessment for Business Environment Risk Intelligence (BERI) in the US and Switzerland.

Daniel holds an MBA with honours from the Institut d’Etudes Politiques in Paris and a MA in International Political Economy from the American University in Washington DC.

Daniel enjoys wine tasting and skiing, and is personally committed to support vulnerable children in Sub-Saharan Africa. He lives in Geneva with his wife and their three young daughters.

His favourite question to entrepreneurs: « What makes you passionate about your business? »